"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Human vaccines & immunotherapeutics Ročník 18; číslo 3; s. 1889449
Hlavní autoři:	Sollena, Pietro, Cappilli, Simone, Federico, Francesco, Schinzari, Giovanni, Tortora, Giampaolo, Peris, Ketty
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Taylor & Francis 31.05.2022 Taylor & Francis Group
Témata:	Advanced melanoma Antibodies, Monoclonal - adverse effects Antineoplastic Agents, Immunological - adverse effects CTLA-4 Antigen - antagonists & inhibitors CTLA-4 inhibitors cutaneous adverse events Exanthema - chemically induced Humans immune checkpoint inhibitors Immunotherapy - adverse effects Melanoma - drug therapy Melanoma – Mini-Review PD-1 inhibitors skin rash skin rash cutaneous adverse events PD-1 inhibitors immune checkpoint inhibitors Advanced melanoma CTLA-4 inhibitors
ISSN:	2164-5515, 2164-554X, 2164-554X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as "skin rash", and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.
AbstractList	Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as "skin rash", and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as "skin rash", and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management. Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated protein 4, anti-programmed cell death protein 1 and its ligand inhibitors have been approved for advanced melanoma among other solid cancers. Although immunotherapy demonstrated a good safety profile, a new spectrum of multisystemic immune-related adverse events has been recently reported due to their use. Cutaneous reactions represent one of the leading adverse events, often reported in literature as "skin rash", and rarely further characterized in distinct dermatologic entities. Herein we describe the distinctive cutaneous rashes occurring during immunotherapies for advanced melanoma, discussing implications in the treatment management.
Author	Cappilli, Simone Schinzari, Giovanni Federico, Francesco Peris, Ketty Sollena, Pietro Tortora, Giampaolo
Author_xml	– sequence: 1 givenname: Pietro surname: Sollena fullname: Sollena, Pietro organization: Fondazione Policlinico Universitario A. Gemelli IRCCS – sequence: 2 givenname: Simone surname: Cappilli fullname: Cappilli, Simone organization: Università Cattolica del Sacro Cuore – sequence: 3 givenname: Francesco surname: Federico fullname: Federico, Francesco organization: Fondazione Policlinico Universitario A. Gemelli IRCCS – sequence: 4 givenname: Giovanni surname: Schinzari fullname: Schinzari, Giovanni organization: Fondazione Policlinico Universitario A. Gemelli IRCCS – sequence: 5 givenname: Giampaolo surname: Tortora fullname: Tortora, Giampaolo organization: Fondazione Policlinico Universitario A. Gemelli IRCCS – sequence: 6 givenname: Ketty orcidid: 0000-0002-5237-0463 surname: Peris fullname: Peris, Ketty email: ketty.peris@unicatt.it organization: Università Cattolica del Sacro Cuore
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33759689$$D View this record in MEDLINE/PubMed
BookMark	eNqFkk1vEzEQhleoiJbSnwBa9cQlwfbaXi9ICFTxUalSD4DEzZr4I3FZ28F2gnLgv-M0aUR7AF_sGb_zzNgzT5ujEINpmucYTTES6BXBnDKG2ZQggqdYiIHS4VFzsvVPGKPfjw5nzI6bs5xvUF09IpTzJ81x1_Vs4GI4aX6ff_nhQpsgL0w-byHo1nm_CrEsTILlpq2X3owQoofXrXa5uKBKq03yUOIY5061oNcmZdOatQkl7xnL0SkoLobc2pjaHc6sStV7CDA3voqfNY8tjNmc7ffT5tvHD18vPk-urj9dXry_mijW0TLRiCvUEdxZzenMUm5tN2BCB01otTAwApgSoKgXbDC4GqJngGZUWGwF7k6byx1XR7iRy-Q8pI2M4OStI6a5hFRLG40UymDMtei15bRTQnBKEZsxBBoJrrastzvWcjXzRqv6jATjPej9m-AWch7XslZMOtRXwMs9IMWfK5OL9C4rM9ZPNnGVJWGI9nUJUaUv_s51SHLXvypgO4FKMedk7EGCkdyOirwbFbkdFbkflRr35kGccuW2XbVkN_43-t0u2oXaWw-_Yhq1LLAZY7IJgnJZdv9G_AHumth7
CitedBy_id	crossref_primary_10_1016_j_addr_2024_115315 crossref_primary_10_1016_j_rdc_2024_01_002 crossref_primary_10_2174_0118741207369739250423073032 crossref_primary_10_1016_j_toxrep_2025_102021 crossref_primary_10_1111_ijd_17520 crossref_primary_10_3390_membranes13070671 crossref_primary_10_3389_fonc_2022_924849
Cites_doi	10.1016/j.chest.2018.03.056 10.1186/s40425-018-0323-0 10.1093/annonc/mdx225 10.1097/CMR.0000000000000017 10.5070/D3268049887 10.14694/EdBook_AM.2015.35.76 10.1016/j.jaad.2020.03.132 10.1016/j.annonc.2019.10.008 10.1016/j.jaad.2018.10.062 10.1016/j.jaad.2020.05.045 10.1111/cup.12858 10.1093/jjco/hyaa139 10.1111/bjd.13058 10.1007/s00520-020-05701-9 10.1016/j.immuni.2019.12.011 10.1001/jamaoncol.2017.2391 10.1016/j.jaad.2020.08.137 10.1186/s40425-016-0151-z 10.1177/1078155219881181 10.1016/S1470-2045(18)30700-9 10.1097/CMR.0000000000000261 10.1684/ejd.2014.2297 10.1016/S1470-2045(19)30388-2 10.1158/2326-6066.CIR-17-0220 10.1038/s41571-020-0352-8 10.1634/theoncologist.2018-0531 10.1016/j.jaad.2015.10.029 10.1016/j.jaad.2013.11.022 10.1016/j.jdermsci.2016.12.019 10.1111/ajd.12594 10.1245/s10434-019-07963-y 10.1111/dth.13074 10.1111/dth.14618 10.1016/j.jaad.2014.06.042 10.21037/tgh.2019.09.05 10.1177/1078155220906885 10.1016/j.ejca.2016.02.010 10.1016/j.ejca.2020.02.024 10.1001/jamadermatol.2016.2226 10.1007/s40257-014-0092-6 10.1080/19381980.2016.1199307 10.1016/j.jaad.2018.05.035 10.1097/CMR.0000000000000642 10.1097/CCO.0000000000000290 10.1001/jamadermatol.2018.1912 10.5070/D3265048774 10.1016/j.semcancer.2019.06.021 10.1016/j.path.2019.11.002 10.1007/s40257-017-0336-3 10.1186/s40425-016-0157-6 10.1097/DAD.0000000000000688 10.1016/S1470-2045(20)30494-0 10.1093/annonc/mdw443 10.1097/CMR.0000000000000397 10.1111/ced.13399 10.1111/jdv.14282 10.1080/0284186X.2020.1818823 10.1634/theoncologist.2018-0128 10.3389/fonc.2020.00091 10.1111/ijd.15163 10.1136/jitc-2019-000260 10.1016/j.jaad.2019.12.068
ContentType	Journal Article
Copyright	2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 The Author(s)
Copyright_xml	– notice: 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 – notice: 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 2021 The Author(s)
DBID	0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.1080/21645515.2021.1889449
DatabaseName	Taylor & Francis Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 4 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
DocumentTitleAlternate	P. SOLLENA ET AL
EISSN	2164-554X
ExternalDocumentID	oai_doaj_org_article_8ce116d87df643c8864405b50ad086c1 PMC9122307 33759689 10_1080_21645515_2021_1889449 1889449
Genre	Research Article Journal Article
GroupedDBID	--- 00X 0YH 30N 4.4 53G AALUX ABEIZ ABUPF ACGFS ADBBV ADCVX AECIN AENEX AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQTUD ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG DGEBU DIK EBS EMOBN GROUPED_DOAJ H13 HYE KYCEM LJTGL M4Z O9- RPM SV3 TDBHL TFL TFW TTHFI AAYXX CITATION CGR CUY CVF ECM EIF NPM RIG 7X8 5PM IPNFZ
ID	FETCH-LOGICAL-c534t-d06c03213fd64bf46ff391249d24f461a52a142a407859e1a14875a0b48f1f813
IEDL.DBID	TFW
ISICitedReferencesCount	9
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000632335700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2164-5515 2164-554X
IngestDate	Fri Oct 03 12:41:37 EDT 2025 Tue Nov 04 01:48:13 EST 2025 Fri Sep 05 10:00:52 EDT 2025 Mon Jul 21 06:07:25 EDT 2025 Sat Nov 29 04:02:26 EST 2025 Tue Nov 18 21:10:09 EST 2025 Mon Oct 20 23:48:30 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	3
Keywords	skin rash cutaneous adverse events PD-1 inhibitors immune checkpoint inhibitors Advanced melanoma CTLA-4 inhibitors
Language	English
License	open-access: http://creativecommons.org/licenses/by-nc-nd/4.0/: http://creativecommons.org/licenses/by-nc-nd/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c534t-d06c03213fd64bf46ff391249d24f461a52a142a407859e1a14875a0b48f1f813
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-5237-0463
OpenAccessLink	https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1889449
PMID	33759689
PQID	2504777788
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2504777788 pubmed_primary_33759689 crossref_primary_10_1080_21645515_2021_1889449 doaj_primary_oai_doaj_org_article_8ce116d87df643c8864405b50ad086c1 informaworld_taylorfrancis_310_1080_21645515_2021_1889449 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9122307 crossref_citationtrail_10_1080_21645515_2021_1889449
PublicationCentury	2000
PublicationDate	2022-05-31
PublicationDateYYYYMMDD	2022-05-31
PublicationDate_xml	– month: 05 year: 2022 text: 2022-05-31 day: 31
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Human vaccines & immunotherapeutics
PublicationTitleAlternate	Hum Vaccin Immunother
PublicationYear	2022
Publisher	Taylor & Francis Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Group
References	cit0033 cit0034 cit0031 cit0032 cit0030 cit0039 cit0037 cit0038 cit0035 cit0036 cit0022 cit0023 cit0020 cit0021 cit0062 cit0063 Muntyanu A (cit0055) 2020 cit0060 cit0061 cit0028 cit0029 cit0026 cit0027 cit0024 cit0025 cit0011 cit0012 cit0056 cit0053 cit0010 cit0054 cit0051 cit0052 cit0050 cit0019 cit0017 cit0018 cit0015 cit0059 cit0016 cit0013 cit0057 cit0014 cit0058 cit0044 cit0001 cit0045 cit0042 cit0043 cit0040 cit0041 cit0008 cit0009 cit0006 cit0007 cit0004 cit0048 cit0005 cit0049 cit0002 cit0046 cit0003 cit0047
References_xml	– ident: cit0061 doi: 10.1016/j.chest.2018.03.056 – ident: cit0062 doi: 10.1186/s40425-018-0323-0 – ident: cit0024 doi: 10.1093/annonc/mdx225 – ident: cit0040 doi: 10.1097/CMR.0000000000000017 – ident: cit0057 doi: 10.5070/D3268049887 – ident: cit0017 doi: 10.14694/EdBook_AM.2015.35.76 – ident: cit0008 doi: 10.1016/j.jaad.2020.03.132 – ident: cit0007 doi: 10.1016/j.annonc.2019.10.008 – ident: cit0028 doi: 10.1016/j.jaad.2018.10.062 – ident: cit0020 doi: 10.1016/j.jaad.2020.05.045 – ident: cit0016 doi: 10.1111/cup.12858 – ident: cit0003 doi: 10.1093/jjco/hyaa139 – ident: cit0052 doi: 10.1111/bjd.13058 – ident: cit0063 doi: 10.1007/s00520-020-05701-9 – ident: cit0001 doi: 10.1016/j.immuni.2019.12.011 – ident: cit0019 doi: 10.1001/jamaoncol.2017.2391 – ident: cit0032 doi: 10.1016/j.jaad.2020.08.137 – ident: cit0053 doi: 10.1186/s40425-016-0151-z – ident: cit0050 doi: 10.1177/1078155219881181 – ident: cit0010 doi: 10.1016/S1470-2045(18)30700-9 – ident: cit0046 doi: 10.1097/CMR.0000000000000261 – ident: cit0045 doi: 10.1684/ejd.2014.2297 – ident: cit0025 doi: 10.1016/S1470-2045(19)30388-2 – ident: cit0058 doi: 10.1158/2326-6066.CIR-17-0220 – ident: cit0035 doi: 10.1038/s41571-020-0352-8 – ident: cit0030 doi: 10.1634/theoncologist.2018-0531 – ident: cit0037 doi: 10.1016/j.jaad.2015.10.029 – ident: cit0042 doi: 10.1016/j.jaad.2013.11.022 – ident: cit0034 doi: 10.1016/j.jdermsci.2016.12.019 – ident: cit0049 doi: 10.1111/ajd.12594 – ident: cit0006 doi: 10.1245/s10434-019-07963-y – ident: cit0039 doi: 10.1111/dth.13074 – ident: cit0059 doi: 10.1111/dth.14618 – ident: cit0043 doi: 10.1016/j.jaad.2014.06.042 – ident: cit0005 doi: 10.21037/tgh.2019.09.05 – ident: cit0044 doi: 10.1177/1078155220906885 – ident: cit0013 doi: 10.1016/j.ejca.2016.02.010 – ident: cit0060 doi: 10.1016/j.ejca.2020.02.024 – ident: cit0014 doi: 10.1001/jamadermatol.2016.2226 – ident: cit0038 doi: 10.1007/s40257-014-0092-6 – ident: cit0051 doi: 10.1080/19381980.2016.1199307 – start-page: 120347542094326 year: 2020 ident: cit0055 publication-title: J Cutan Med Surg – ident: cit0029 doi: 10.1016/j.jaad.2018.05.035 – ident: cit0056 doi: 10.1097/CMR.0000000000000642 – ident: cit0023 doi: 10.1097/CCO.0000000000000290 – ident: cit0027 doi: 10.1001/jamadermatol.2018.1912 – ident: cit0031 doi: 10.5070/D3265048774 – ident: cit0002 doi: 10.1016/j.semcancer.2019.06.021 – ident: cit0004 doi: 10.1016/j.path.2019.11.002 – ident: cit0018 doi: 10.1007/s40257-017-0336-3 – ident: cit0054 doi: 10.1186/s40425-016-0157-6 – ident: cit0015 doi: 10.1097/DAD.0000000000000688 – ident: cit0026 doi: 10.1016/S1470-2045(20)30494-0 – ident: cit0033 doi: 10.1093/annonc/mdw443 – ident: cit0048 doi: 10.1097/CMR.0000000000000397 – ident: cit0041 doi: 10.1111/ced.13399 – ident: cit0047 doi: 10.1111/jdv.14282 – ident: cit0011 doi: 10.1080/0284186X.2020.1818823 – ident: cit0021 doi: 10.1634/theoncologist.2018-0128 – ident: cit0009 doi: 10.3389/fonc.2020.00091 – ident: cit0036 doi: 10.1111/ijd.15163 – ident: cit0012 doi: 10.1136/jitc-2019-000260 – ident: cit0022 doi: 10.1016/j.jaad.2019.12.068
SSID	ssj0000702466
Score	2.3189201
Snippet	Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system,... Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient’s immune system,...
SourceID	doaj pubmedcentral proquest pubmed crossref informaworld
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1889449
SubjectTerms	Advanced melanoma Antibodies, Monoclonal - adverse effects Antineoplastic Agents, Immunological - adverse effects CTLA-4 Antigen - antagonists & inhibitors CTLA-4 inhibitors cutaneous adverse events Exanthema - chemically induced Humans immune checkpoint inhibitors Immunotherapy - adverse effects Melanoma - drug therapy Melanoma – Mini-Review PD-1 inhibitors skin rash
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTtwwELYq1EpcKvoDXUorV-IaiB07cbgBKuqhQj2Uipvl-EesxGbRJiBxg_egL8eTMONkt1mEtJfuLU68ij1jz0w8832E7BYB4gyOn97KCKrtfVJa5hLvfagq9Fgj89yfn8XpqTo_L38NqL4wJ6yDB-4mbl9Zz1juVOECGE-rFBjwVFYyNQ68cRsDH_B6BsFU3IMLsD3xoJJDPJCAWyDn5Tsq3cc2bILwkLM9plQpEEtzYJgifv8z9NKXfNDnqZQD23SyQd72TiU97Abzjrzy9XvypqOZvP1A7h_vHpBki85Mc-Gbx7u_1NSOjrE0pC_AuqVwe-IvTT2dmAPqcOXXtqUON-622yCpQfLmxtMI-tT0__Hv_JvCIOignotOFqk1H8nZyfffxz-SnnohsTITbeLS3KYZZ1lwuaiCyEPISuSpdlzAFTOSGya4wVNAWXoGFxD4mLQSKrCgWLZJ1upp7T8R6osqcHCEhOdWgMNQGSsVOFFOGsYhAB8RMZ93bXtccqTHuNSshy-di0ujuHQvrhHZW3S76oA5VnU4QqEuHkZc7dgA2qZ7bdOrtG1EyqFK6DZ-VgkdB4rOVrzAt7n-aFjDeDBjaj-9bjTCyBXww8nY6vRp8ZpZVsgyV9C7WNK0pXEs36nHFxEnHASGaf7b_2Pgn8k6x8KPmDexQ9ba2bX_Ql7bm3bczL7GxfcEDkkvQw priority: 102 providerName: Directory of Open Access Journals
Title	"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management
URI	https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1889449 https://www.ncbi.nlm.nih.gov/pubmed/33759689 https://www.proquest.com/docview/2504777788 https://pubmed.ncbi.nlm.nih.gov/PMC9122307 https://doaj.org/article/8ce116d87df643c8864405b50ad086c1
Volume	18
WOSCitedRecordID	wos000632335700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: DOA dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: TFW dateStart: 20180102 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 2164-554X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000702466 issn: 2164-5515 databaseCode: 0YH dateStart: 20220101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagAokL5c1SWJmKa0rsOInTW0GsekAVhwLLyXL8aFfqZtEmReqB_86M44TdCtQD5BApj0mcydgzY898Q8ib0oOfwXHqrQqg2s4llWE2cc75ukaLNVSe-_KxPDmR83n1KUYTtjGsEn1o3wNFhLEaO7eu2yEi7i0HEx8UfQ7eHWcHTMpKCEzhA9WPNQxOZ1_HWRYQaN4vWCJRglRDGs_fHrSloAKO_zUU0z_ZotdDKjd01Gz3P3zdA3I_Gqj0qJeoh-SWax6Ru33JyqvH5Oc-luuia92eu3afwlvoAlNMYiLXFYWLS3ehm9VSH1KLI0hjOmpRAXT9QEs1FoFuHQ3gUW18xu91dApMoBt5YXQ5hug8IZ9nH07fHyexhENi8kx0iU0Lk2acZd4Wovai8D6rsN615QKOmM65ZoJrXE3MK8fgABwondZCeuYly56SnWbVuOeEurL2HAwq4bgRYHjU2uQSjDGba8bBkZ8QMfw3ZSK-OZbZuFAswqAOnFXIWRU5OyEHI9n3HuDjJoJ3KBTjzYjPHU6s1mcqdncljWOssLK0Hkw-IyWYnWle56m24EMaNiHVpkipLkzP-L6WispuaMDrQf4UjAW4wKMbt7psFcLRlbAhM5718jg2M8vKvCokUJdbkrr1HdtXmsV5wBuHH4bpAi_-oc175B7HvJEQdvGS7HTrS_eK3DE_ukW7npLb6bdj2JdzOQ2TItPQi38B4R4_VA
linkProvider	Taylor & Francis
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaggODC-7E8TcU1bezYicMNENUilj0VVE6W4wddqZtFmxSpB_47M86D3QrUA-SWZCfrTMb2jD3zfYS8KgLEGRyX3soIqu19UlrmEu99qCr0WCPz3JdZMZ-ro6NysxYG0yoxhg4dUEQcq7Fz42L0kBK3z8HHh5leQnjH2R5TqhSivEyuSGTOBptOv07HdRYwad5tWaJUgmJDIc_fnrQ1RUUk_3M4pn_yRs8nVW7MUge3_sf73SY3ex-VvumM6g655Ou75FrHWnl2j_zcRcYuujbNsW92KfwNXWCVSV_LdUbh5tKfmHq1NK-pw0Gkti11OAe03VhLDfJAN55G_Kimf8bvrXQKWqAbpWF0OWbp3CefD94fvpsmPYtDYmUm2sSluU0zzrLgclEFkYeQlUh57biAM2YkN0xwgxuKsvQMTiCGMmklVGBBsewB2alXtX9EqC-qwMGnEp5bAb5HZaxU4I85aRiHWH5CxPDhtO0hzpFp40SzHgl10KxGzepesxOyN4p97zA-LhJ4i1Yx_hghuuOF1fqb7nu8VtYzljtVuABen1UKPM9UVjI1DsJIyyak3LQp3cYVmtDRqejsgga8HAxQw3CAezym9qvTRiMiXQEHKuNhZ5BjM7OskGWuQLrYMtWt99i-Uy-OI-Q4fDCsGHj8D21-Qa5PDz_N9OzD_OMTcoNjGUnMwnhKdtr1qX9Grtof7aJZP48d-BcQ7EB0
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagPMSF92N5mopr2thxEocbrxWIatVDgd4sxw-6UjdbbVKkHvjvzDhO2K1APUBuSXayzmRsf2PPfEPIq9KDn8Fx6a0KpNrOJZVhNnHO-bpGxBoqz33dK2czeXhY7cdowjaGVaIP7XuiiDBWY-c-sX6IiNvlAPFhos_Bu-Nsh0lZCVFdJlcAOhfofx1Mv43LLGDRvN-xRKkExYY8nr89aWOGCkT-52hM_wRGz8dUrk1S01v_4fVuk5sRodI3vUndIZdcc5dc62tWnt0jP7exXhdd6fbItdsU_oXOMcckZnKdUbi5cMe6WS70a2pxCGlMRy3OAF0_0lKNVaBbRwN7VBuf8XsjnYIS6FpiGF2MMTr3yZfph4N3H5NYwyExeSa6xKaFSTPOMm8LUXtReJ9VWPDacgFnTOdcM8E1bifmlWNwAh6UTmshPfOSZQ_IVrNs3CNCXVl7DohKOG4EII9am1wCGrO5Zhw8-QkRw3dTJhKcY52NY8UiD-qgWYWaVVGzE7Izip30DB8XCbxFoxh_jATd4cJy9V3F_q6kcYwVVpbWA-YzUgLuTPM6T7UFJ9KwCanWTUp1YX3G98VUVHZBA14O9qdgMMAdHt245WmrkI-uhAOV8bC3x7GZWVbmVSFButyw1I332LzTzI8C4Th8MMwXePwPbX5Bru-_n6q9T7PPT8gNjjkkIQTjKdnqVqfuGblqfnTzdvU8dN9fecE_YQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%22Skin+rashes%22+and+immunotherapy+in+melanoma%3A+distinct+dermatologic+adverse+events+and+implications+for+therapeutic+management&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Sollena%2C+Pietro&rft.au=Cappilli%2C+Simone&rft.au=Federico%2C+Francesco&rft.au=Schinzari%2C+Giovanni&rft.date=2022-05-31&rft.pub=Taylor+%26+Francis&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=18&rft.issue=3&rft_id=info:doi/10.1080%2F21645515.2021.1889449&rft.externalDBID=0YH&rft.externalDocID=1889449
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon